The Role of Serum Leptin Levels in Multiple Sclerosis Disease Activity While on Interferon Beta 1a (Rebif) Treatment (Leptin)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
To determine a correlation between serum leptin levels, nitric oxide preceding a relapse and change in leptin and nitric oxide levels during exacerbation in relapsing remitting multiple sclerosis patients.
Condition or disease
This is an observational pilot study in patients with definitive relapsing-remitting multiple sclerosis to determine whether there is a correlation in serum leptin levels and serum nitric oxide levels during a clinically observed increase in disease activity. Each subject will followed for 12 months while taking interferon beta-1a subcutaneous injections 3 times a week.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 60 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
USF Medical Clinic Tampa, Flrida
Confirmed diagnosis of multiple sclerosis per update of McDonald criteria
Initiating treatment with interferon beta 1a subcutaneous injection with minimal dosing of 22mcg.
18-60 years of age.
Women who are not pregnant or breast feeding, and who do not intend to become pregnant.
Stable dose of concomitant medications for 30 days prior to baseline. Efforts should be made to maintain steady doses of concomitant medications for the duration of the study.
Treatment on other interferon preparations, glatiramer acetate, in last 30 days or 6 months on Natalizumab, mitoxantrone, cyclosporine or other immunomodulators as determined by the PI.
Treatment with any other investigational treatments within the past year or treatment with any investigational treatments for multiple sclerosis within the last year.
Any progressive form of MS.
Known Hypersensitivity to interferon beta 1a.
Inability to administer subcutaneous injections
Inability to undergo laboratory evaluation.
Seropositivity for HIV (by medical history)
Diabetes Mellitus Tyle I or II (by medical history)
Hepatitis B or C (by medical history)
Uncontrolled psychiatric disorder.
Any unstable illness that the investigator's opinion precludes participation in this study.
Inability to maintain compliance with study protocol.
Implanted devices or metal which would contraindicate MRI.
Clinically significant abnormalities in CBC or CMP